Pharmion Corp. (PHRM)

All Comments on PHRM

  • commenter
    LikeItIs
    Aug 23 08:22 PM
    Biotech Day in Review: Hopeful Results from HIV Conference [view article]
    NVAX keeps working on it!! Reply
  • commenter
    Olboy2
    Aug 13 02:56 PM
    Cancer Stocks on the Go: Winners and Losers [view article]
    I agree with paviov, However I would like to know about the new developments the phase II and III studies that are going well, where is the advancement taking place, how close to a cure, what company has the potential winning drug ?? Reply
  • commenter
    User 192949
    May 14 02:35 AM
    Biotech Day in Review: Hopeful Results from HIV Conference [view article]
    is a fastest service. Reply
  • commenter
    Daniel
    Jacome
    Apr 10 05:07 PM
    My Website
    Pharmion: The Small Drug Maker That Could (PHRM) [view article]
    PHRM was recently acquired by CELG for a large 60% premium, we are discontinuing coverage. Reply
  • commenter
    SeekingAlpha
    Editors
    Apr 06 05:17 AM
    My Website
    General Discussion on PHRM
    Is this a buy or a sell? Reply
  • commenter
    retired
    pharma
    Mar 16 11:21 AM
    My Website
    European Hedge: Pharmion and Celgene [view article]
    perhaps Thalomid becomes the accepted MM component and not Revlomid due to no real differences in efficacy,safety but Thal is less expensive.In fact Celg buys Pharmion for just this reason to control both scenarios and if Vidaza comes through a huge potential plus down the road in their growth story! Thal pricing is much lower than Rev~ $65,000/years treatment. This is the concern of the EC! Thal is the accepted IMid of first choice and Rev is canabalizing and driving up MM cost of therapy! This can only go on for so long before the market takes notice! Perhaps that is why the post merger Celg price seems stuck at 56 at least in the Short term. They will need super sales reported in Q1 to catalize new growth. With MLNM on the brink of 1st line approval of Velcade in MM I do not see that happening! Reply
  • commenter
    mikehav
    Dec 16 02:24 PM
    My Website
    A Super(Gen) Play on Cancer Biotech Consolidation [view article]
    Thanks for the nice comments! Reply
  • commenter
    jturano7423
    Dec 16 11:30 AM
    A Super(Gen) Play on Cancer Biotech Consolidation [view article]
    I applaud you Mike Havrilla for this extremely interesting article re:supg. This is the kind of stock to invest in as a safer speculative stock than some
    others who have horrific balance sheets and a management team who is counter-productive to its
    own company. Most important to me on biotech's is pipeline, success with past phases and results, little or no debt, and high REO(return on equity).
    You did a superb due diligence on this company.
    Thank you again and I hope you can continue to be the Beacon of Light in the future for all investors who are privileged to read your articles on the Seeking Alpha Site.
    JIMMY T
     Reply
  • commenter
    Daniel
    Jacome
    Nov 22 11:03 PM
    My Website
    Why Acquiring Pharmion Makes Sense for Celgene [view article]
    you get PHRM cost structure embedded in Celgenes -- it makes sense. Then CELG gets a 10B potential drug dynasty for < 3B.....good deal for PHRM investors.

    Keep an eye on SUPG, arguably the next one to get gobbled up.     Reply
  • commenter
    Alan
    Brochstein
    Jul 23 08:10 AM
    My Website
    Cancer Stocks: Lagging Again [view article]
    I am no longer submitting Cancer Stocks Weekly to Seeking Alpha, but I will be back with a Quarterly in early October. For those who are interested in continuing to see it (free of charge), email me and I will be happy to send it directly to you on a weekly basis. Alternatively, I will continue to submit it to biohealthinvestor.com. Reply
  • commenter
    Alan
    Brochstein
    Jun 18 12:54 PM
    My Website
    Cancer Stocks Slide Again [view article]
    I wanted to point out an error in the article - GNVC is developing a pancreatic cancer treatment (not vaccine). Reply
  • commenter
    Alan
    Brochstein
    Jun 11 02:51 PM
    My Website
    Cancer Stocks Plunge Following ASCO Meeting [view article]
    Miles, I have a negative bias towards small biotech companies, especially ones like this that have a terrible history of underperforming the stock market, generating losses and diluting with equity issuance. That isn't to say that one might find a diamond in the garbage can, but, I think that one is actually more likely to find a diamond in the garbage can. If one of these companies is creating a truly novel, revolutionary treatment, I personally believe that an investor would have plenty of time to buy later at a higher price and still make a ton of money.

    Note, I don't have an opinion specifically on Insmed other than my general observations in the above paragraph.     Reply
  • commenter
    milesjrobert
    s
    Jun 11 12:00 PM
    Cancer Stocks Plunge Following ASCO Meeting [view article]
    Dear Sir,
    What is your current opinion on Insmed?
    Thank you very much,
    Miles Roberts     Reply
  • commenter
    Mr Mister
    Jun 04 06:00 PM
    Cancer Stocks Soar With Annual ASCO Meeting [view article]
    Your table is too over-crowded to be useful. Next time skip the industry, HQ city and state as it is meaningless except for job seekers. Nice try though. Reply
Loading...
Symbols:
Authors:
Quick Links: